In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
|Poll|April 29, 2019
A 54-Year-Old Woman With Nausea and Vomiting
Author(s)Cesar A. Moran, MD
A 54-year-old woman presents with nausea, vomiting, and flushing. Imaging shows a mass in the right adrenal gland. What is your diagnosis?
Advertisement
A 54-year-old woman presents with nausea, vomiting, and flushing. Imaging shows a mass in the right adrenal gland.
Based on the image shown, what is your diagnosis?
Advertisement
Related to this article
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
5